AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
In your 20s, it's crucial to know what financial mistakes to avoid. Discover key insights to help you manage your money wisely.
26,712 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Regulated banks can custody crypto and settle tokenized funds, but Basel's capital rules impose a punishing cost that...
Taylor Morrison’s proxy shows a patient, staged sale to Berkshire Hathaway, highlighting a cautious appetite for big-...
CoreWeave tumbled in morning trading as a legal case, insider sales and high leverage raise questions about its path ...
A new Brookings-FED working paper casts doubt on ai’s $2.2 trillion deficit savings, warning that disruption and poli...
XRP is testing a critical price level in 2026 as regulatory clarity improves and ETF access expands. Analysts debate ...
U.S. equities closed the second quarter with a double‑digit rally, led by AI-driven tech names. Yet analysts warn tha...
Bitcoin steadied near mid-$60,000s as oil prices jumped after Washington moved to tighten Iran-related waivers. A Jul...
A tech-enabled, just-in-time oil logistics network helped cap price spikes amid geopolitical volatility. This report ...
Cardano founder Charles Hoskinson publicly rejects retirement rumors that spread across social media and even reached...
The Strait of Hormuz remains blocked by a widening U.S.-Iran conflict, fueling volatility in oil prices and household...
A disciplined investment approach blends steady dividend payers with selective high-yield assets to produce durable i...